About Event

Welcome to the Inaugural Cell & Gene Therapy Pricing & Reimbursement Summit

In the ever-evolving realm of healthcare, cell and gene therapies stand at the forefront, offering not just hope but tangible solutions for curing diseases and achieving sustained remission. The transformative potential of these therapies cannot be overstated, yet challenges persist in ensuring widespread access and affordability. 

The Cell & Gene Therapy Pricing & Reimbursement Summit is where influential Directors and Vice Presidents of Pricing, Market Access, Strategy converge to address these critical issues head-on.  

By fostering partnerships and leveraging collective expertise, we are poised to pave the way for the successful introduction of these groundbreaking therapies. Join us as we navigate the path towards a future where equitable access to life-changing treatments is not just a goal, but a reality. 

DISCOVER

ENGAGE

GAIN

how leading companies are navigating the evolving regulatory landscape to tackle complex challenges and gain strategic insights 

with industry experts to enhance patient access and ensure the success of commercial cell and gene therapy launches

knowledge into the impact of the IRA and the latest pricing models

Join Fellow Pricing, Market Access & Reimbursement Experts to:

Evvnt Square (27)

Connect with other industry leaders to expand your professional network and foster valuable collaborations with Novartis, uniQure, Gilead, Pfizer and many more 

Evvnt Square (28)

Gain insights on the CMS Coverage with Evidence Development Model to understand the real-world evidence and health economics perspective with Duke-Margolis Center for Health Policy, Tufts Medical Centers & Oklahoma Health Care Authority

Evvnt Square (30)

Acquire actionable strategies on global healthcare budgeting structures and analyze their ability to handle large one-time payments to better allocate funds with Ultragenyx and bluebird bio 
 

Evvnt Square (31)

Discuss the latest approvals to gain insights into the evolving landscape of public payment dynamics and become a strategic decision-maker with CSL Behring discussing the progress of HEMGENIX

Evvnt Square (32)

Learn directly from the Centers for Medicare & Medicaid Services the implications of the Inflation Reduction Act to build clarity on regulatory impacts 

What our speakers have to say:

“Aligning on key market trends, identifying challenges to access, particularly from a reimbursement standpoint, and developing potential solutions to these challenges are all critical to ensuring individuals may benefit from the transformational innovation of novel cell and gene therapies.”

Laura Okpala, Executive Director, US Reimbursement Policy, Gilead Sciences